Cargando…

Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma

SIMPLE SUMMARY: Renal cell carcinoma is particularly characterized by its high vascularization and dense immune cells infiltration. The angiogenesis blockade in combination with immune checkpoint inhibitors have supposed milestones in the treatment landscape of this tumor. This article gathers the a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballesteros, Pablo Álvarez, Chamorro, Jesús, Román-Gil, María San, Pozas, Javier, Gómez Dos Santos, Victoria, Granados, Álvaro Ruiz, Grande, Enrique, Alonso-Gordoa, Teresa, Molina-Cerrillo, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656474/ https://www.ncbi.nlm.nih.gov/pubmed/34885091 http://dx.doi.org/10.3390/cancers13235981

Ejemplares similares

Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020)

Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2022)

Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
por: San Román Gil, María, et al.
Publicado: (2020)

Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms
por: Pozas, Javier, et al.
Publicado: (2019)

BRAF Mutated Colorectal Cancer: New Treatment Approaches
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020)

Novel Tyrosine Kinase Targets in Urothelial Carcinoma
por: Torres-Jiménez, Javier, et al.
Publicado: (2021)

May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia
por: Molina-Cerrillo, Javier, et al.
Publicado: (2021)

Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
por: Alonso-Gordoa, Teresa, et al.
Publicado: (2019)

Tyrosine Kinase Receptors in Oncology
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2020)

Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance
por: Araujo-Castro, Marta, et al.
Publicado: (2021)

Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?
por: Pozas, Javier, et al.
Publicado: (2022)

Primary Neuroendocrine Tumor of the Parotid Gland: A Case Report and a Comprehensive Review of a Rare Entity
por: Martínez-Sáez, Olga, et al.
Publicado: (2016)

The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide
por: Serrano Domingo, Juan José, et al.
Publicado: (2021)

Bronchial Carcinoids: From Molecular Background to Treatment Approach
por: Araujo-Castro, Marta, et al.
Publicado: (2022)

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
por: Alonso-Gordoa, Teresa, et al.
Publicado: (2015)

Current Landscape of Immunotherapy for Advanced Sarcoma
por: Albarrán, Víctor, et al.
Publicado: (2023)

Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report
por: Pozas, Javier, et al.
Publicado: (2022)

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
por: Comandone, Alessandro, et al.
Publicado: (2021)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
por: Furukawa, Koichi, et al.
Publicado: (2020)

Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
por: González, Alicia, et al.
Publicado: (2021)

Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
por: Grande, Enrique, et al.
Publicado: (2017)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
por: San-Román-Gil, María, et al.
Publicado: (2023)

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
por: García-Martínez, Elena, et al.
Publicado: (2020)

Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature
por: Torrado, Carlos, et al.
Publicado: (2023)

The role of immunotherapy in non-clear cell renal cell carcinoma
por: Climent, Carla, et al.
Publicado: (2023)

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
por: Raybould, Alison L, et al.
Publicado: (2020)

Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences
por: Santoni, Matteo, et al.
Publicado: (2023)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
por: Kashyap, Abhishek S., et al.
Publicado: (2020)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2023)

Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy
por: Rojas, Juan D., et al.
Publicado: (2018)

Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy
por: Esteban, Emilio, et al.
Publicado: (2021)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023)

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
por: Albarrán, Víctor, et al.
Publicado: (2022)

Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
por: Shi, Shujing, et al.
Publicado: (2013)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer
por: Huang, Hao, et al.
Publicado: (2022)

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
por: Li, Haosheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6dpd8rfgveqvvb8j4ih8vjq6hp